Search
Now showing items 1-5 of 5
Nanomedicines for infectious diseases
(Springer Nature, 2019)
Infectious diseases continue to pose a significant threat to global health. Over 200 infectious diseases are currently known to man. Fortunately, only a handful are responsible for significant morbidity and mortality. ...
Acute pharmacokinetics of first line anti-tuberculosis drugs in patients with Pulmonary Tuberculosis and in patients with Pulmonary Tuberculosis co-infected with HIV
(David Publishing, 2011)
The aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with
pulmonary tuberculosis (PTB) and in patients with PTB and HIV during the first 24 h of treatment. Designed as a ...
Determination of kanamycin plasma levels using LC-MS and its pharmacokinetics in patients with multidrug-resistant tuberculosis with and without HIV-infection
(OMICS, 2015)
The objectives of the study were: (1) to determine kanamycin plasma concentrations using liquid
chromatography coupled with mass spectrometry (LC-MS), (2) to investigate kanamycin pharmacokinetics (PK) in
patients with ...
Steady‐state population pharmacokinetics of terizidone and itsmetabolite cycloserine in patients with drug‐resistanttuberculosis
(Wiley, 2019)
Despite terizidone being part of the second‐line recommended drugs fortreatment of drug‐resistant tuberculosis (DR‐TB), information on its pharmacokineticsis scarce. The aim of this study was to describe the steady‐state ...
Amount of cycloserine emanating from terizidone metabolism and relationship with hepatic function in patients with drug resistant tuberculosis
(Springer, 2019)
The dosing of cycloserine and terizidone is the same, as both drugs are considered equivalent
or used interchangeably. Nevertheless, it is not certain from the literature that these drugs are interchangeable. Therefore,
the ...